盐酸埃克替尼治疗中晚期EGFR突变型非小细胞肺癌的效果分析

Effect Analysis of Icotinib Hydrochloride in the Treatment of Intermediate and Advanced EGFR Mutant Non-small Cell Lung Cancer

目的:分析盐酸埃克替尼治疗中晚期表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)的效果。方法:选取北京航天总医院2019年12月至2021年1月期间收治的91例中晚期EGFR突变型NSCLC患者,按照随机数字表法将其分为两组,对照组45例给予多西他赛治疗,观察组46例给予盐酸埃克替尼治疗,观察两组患者临床疗效、免疫功能以及毒副反应发生率。结果:治疗后,观察组患者客观缓解率(65.22%)高于对照组(44.45%),差异具有统计学意义(P<0.05);治疗后,观察组患者CD4^(+)水平高于对照组,CD8^(+)水平低于对照组,差异具有统计学意义(P<0.05);观察组患者各毒副反应发生率和对照组比较差异无统计学意义(P>0.05)。结论:盐酸埃克替尼治疗中晚期EGFR突变型NSCLC患者,可通过调节其免疫功能,提高临床疗效且不增加毒副反应发生率。

Objective To investigate the efficacy of icotinib hydrochloride in the treatment of intermediate and advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).Methods A total of 91 patients with intermediate and advanced EGFR-mutant NSCLC who were admitted to Beijing Aerospace General Hospital from December 2019 to January 2021 were selected and divided into two groups according to random number table method.45 patients in the control group were treated with docetaxel,and 46 patients in the observation group were treated with icotinib hydrochloride.Clinical efficacy,immune function and incidence of toxic and side reactions were observed in two groups.Results After treatment,the objective remission rate of observation group (65.22%) was higher than that of control group (44.45%),and the difference was statistically significant (P < 0.05).After treatment,CD4^(+)level in observation group was higher than control group,CD8^(+)level was lower than control group,the differences were statistically significant (P < 0.05).There was no significant difference in the incidence of adverse reactions between observation group and control group (P > 0.05).Conclusion Icotinib hydrochloride in the treatment of patients with intermediate and advanced EGFR-mutant NSCLC can improve the clinical efficacy without increasing the incidence of toxic reactions by regulating their immune function.